Evidence map›Paper›PMID 34508096›Full record

ArticleNature communications2021

Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo.

Debashis Dutta, Malabendu Jana, Moumita Majumder, Susanta Mondal, Avik Roy, Kalipada Pahan

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
122citing papers in PubMed, 1 pooled it
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

122 citing papers in PubMed, 1 synthesis or guideline pooled it, 178 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. ImpairedNature communications · 2026
    Article
  16. LRRK2NPJ Parkinson's disease · 2026
    Article
  17. Article
  18. Review
  19. Review
  20. Article

62 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Debashis Dutta *Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Malabendu Jana *Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Moumita MajumderDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Susanta MondalDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Avik RoyDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Kalipada PahanDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA. Kalipada_Pahan@rush.edu.ORCID 0000-0001-6048-9598
Rush University Medical Center · US

Funding

Intranasal TIDM peptide for tauopathyR21AG069229 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI PAHAN, KALIPADA · 2020 to 2021
$550k
TLR2-interacting domain of MyD88 peptide for alpha-synucleinopathyR21NS108025 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI PAHAN, KALIPADA · 2018 to 2019
$393k
BLR&D Research Career Scientist ApplicationIK6BX004982 · VA · JESSE BROWN VA MEDICAL CENTER · PI KALIPADA PAHAN · 2020 to 2026
–
BLRD VA IK6 BX004982NIA NIH HHS R21 AG069229NINDS NIH HHS R21 NS108025
6 · The paper itself

Abstract

Pathways to control the spreading of α-synuclein (α-syn) and associated neuropathology in Parkinson's disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB) are unclear. Here, we show that preformed α-syn fibrils (PFF) increase the association between TLR2 and MyD88, resulting in microglial activation. The TLR2-interaction domain of MyD88 (wtTIDM) peptide-mediated selective inhibition of TLR2 reduces PFF-induced microglial inflammation in vitro. In PFF-seeded A53T mice, the nasal administration of the wtTIDM peptide, NEMO-binding domain (wtNBD) peptide, or genetic deletion of TLR2 reduces glial inflammation, decreases α-syn spreading, and protects dopaminergic neurons by inhibiting NF-κB. In summary, α-syn spreading depends on the TLR2/MyD88/NF-κB pathway and it can be reduced by nasal delivery of wtTIDM and wtNBD peptides.

Indexed as

alpha-SynucleinAnimalsCells, CulturedDisease Models, AnimalDopaminergic NeuronsHumansLewy Body DiseaseMiceMice, KnockoutMicrogliaMultiple System AtrophyMutagenesis, Site-DirectedMutationMyeloid Differentiation Factor 88NF-kappa BParkinson Diseasealpha-SynucleinMyd88 protein, mouseMyeloid Differentiation Factor 88NF-kappa BSNCA protein, humanSnca protein, mouseTlr2 protein, mouseToll-Like Receptor 2

Identifiers

PMID34508096
PMCPMC8433339
OpenAlexW3196879829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.